Comparison between ultra-performance liquid chromatography with tandem mass spectrometry and a chemiluminescence immunoassay in the determination of cyclosporin A and tacrolimus levels in whole blood
Author:
Open Access
- 4 October 2013
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 6 (6) , 1535-1539
Abstract
Regular immunosuppressant drug monitoring is important for maintaining the drug concentrations of organ recipients within the therapeutic range. The standardized liquid chromatography-tandem mass spectrometry (LC-TMS) technique has been used for the accurate analysis of immunosuppressive drugs. In the present study, the performance of the recently developed high‑throughput, rapid ultra‑performance liquid chromatography combined with tandem mass spectrometry (UPLC‑TMS) method was validated for the simultaneous measurement of cyclosporin A and tacrolimus in whole blood. The method of measuring cyclosporin A and tacrolimus using UPLC-TMS was established and the precision, limit of detection (LOD), limit of quantitation (LOQ) and matrix effect were validated. In addition, the performance of UPLC-TMS was compared with that of a chemiluminescence immunoassay (CLIA) in >3,400 clinical specimens. The UPLC-TMS revealed a within-run and between‑run precision of <8% and showed a bias of <5%. The LOD and LOQ were 2.0 and 2.5 ng/ml for cyclosporin A, and 0.3 and 0.4 ng/ml for tacrolimus, respectively. Interference from the matrix was not observed. The CLIA measurements of cyclosporin A and tacrolimus showed correlations corresponding with the formulae: Concentration(CLIA) = 1.18 x UPLC-TMS - 5.85; [95% CI: proportional, 1.16‑1.19; constant, -6.86-(-4.81)] and Concentration(CLIA) = 1.14 x UPLC-TMS - 0.38; [(95% CI: proportional, 1.13-1.14; constant, -0.35-(-0.43)], respectively. The majority of results were higher for the immunoassay than for the UPLC-TMS. The newly developed rapid UPLC-TMS method was suitable for use with a large therapeutic concentration range of the analyzed immunosuppressive drugs. Sample preparation was simple and it was possible to detect several immunosuppressants simultaneously, thus significantly lowering the cost of analysis. In conclusion, this method may contribute to improved accuracy and may be preferred to immunoassays for the routine clinical measurement of immunosuppressive drug concentrations in whole blood.Keywords
This publication has 18 references indexed in Scilit:
- Performance Evaluation of Affinity Column Mediated Immunometric Assay for TacrolimusAnnals of Laboratory Medicine, 2009
- Multi-site Analytical Evaluation of the Abbott ARCHITECT Tacrolimus AssayTherapeutic Drug Monitoring, 2009
- Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus ConferenceTherapeutic Drug Monitoring, 2009
- Simultaneous quantification of cyclosporine, tacrolimus, sirolimus and everolimus in whole blood by liquid chromatography–electrospray mass spectrometryClinical Biochemistry, 2008
- The Role of Therapeutic Drug Monitoring in Individualizing Immunosuppressive Drug Therapy: Recent DevelopmentsTherapeutic Drug Monitoring, 2006
- 12-Hour Area Under the Curve Cyclosporine Concentrations Determined by a Validated Liquid Chromatography-Mass Spectrometry Procedure Compared With Fluorescence Polarization Immunoassay Reveals Sirolimus Effect on Cyclosporine PharmacokineticsTherapeutic Drug Monitoring, 2006
- Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometryClinica Chimica Acta, 2004
- Simultaneous Quantification of Sirolimus, Everolimus, Tacrolimus and Cyclosporine by Liquid Chromatography-Mass Spectrometry (LC-MS)Clinical Chemistry and Laboratory Medicine (CCLM), 2002
- Consensus Document: Therapeutic Monitoring of Tacrolimus (FK-506)Therapeutic Drug Monitoring, 1995
- Graft-versus-Host DiseaseNew England Journal of Medicine, 1991